Avanir Pharma Reports Settlement of NUEDEXTA Patent Litigation with Sandoz

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

Avanir Pharmaceuticals,Inc. (NASDAQ: AVNR) today announced that it has entered into a settlementagreement with Sandoz, Inc. to resolve pending patent litigation in responseto Sandoz's abbreviated new drug application (ANDA) seeking approval to marketgeneric versions of Avanir's NUEDEXTA® (dextromethorphanhydrobromide/quinidine sulfate) capsules.The settlement agreement grants Sandoz the right to begin selling a genericversion of NUEDEXTA on July 30, 2026, or earlier under certain circumstances.The parties have also agreed to file a stipulation and order of dismissal withthe United States District Court for the District of Delaware which willconclude this litigation with respect to Sandoz. The settlement does not endAvanir's ongoing litigation against the other four ANDA filers.In compliance with U.S. law, the settlement agreement will be submitted to theU.S. Federal Trade Commission and the Department of Justice where it issubject to review.

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!